NDA 021798 · Bristol Myers Squibb
Baraclude
Entecavir · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Aug 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Mar 29, 2005
Approved uses
9
Original approval plus efficacy supplements
Registered trials
277
40 Phase 3, 15 recruiting
FAERS reports
11,801
10,278 serious, 1,893 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE ACUTE EXACERBATIONS OF HEPATITIS B, PATIENTS CO-INFECTED WITH HIV AND HBV, and LACTIC ACIDOSIS AND HEPATOMEGALY Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including entecavir. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ]. Limited clinical experience suggests there is a potential for the development of resistance to HIV (human immunodeficiency virus) nucleoside reverse transcriptase inhibitors if BARACLUDE is used to treat chronic hepatitis B virus (HBV) infection in patients with HIV infection that is not being treated. Therapy with BARACLUDE is not recommended...
What it is approved for
From the label in effect Nov 6, 2019.
BARACLUDE ® (entecavir) is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. BARACLUDE is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. (1)
Mechanism: Entecavir is an antiviral drug against hepatitis B virus [see Microbiology (12.4) ]. Mechanism of Action Entecavir, a deoxyguanosine nucleoside analogue with activity against HBV reverse transcriptase (rt), is efficiently phosphorylated to the active triphosphate form, which has an intracellular half-life of 15 hours. By competing with the natural substrate deoxyguanosine triphosphate, entecavir triphosphate functionally inhibits all three activities of the HBV reverse transcriptase: (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3)...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 20, 2014 Supplement 19 · Efficacy · priority review LabelLetter
- Oct 12, 2012 Supplement 16 · Efficacy LabelLetter
- Oct 12, 2012 Supplement 14 · Efficacy LabelLetter
- Oct 15, 2010 Supplement 11 · Efficacy Label
- Jul 16, 2009 Supplement 8 · Efficacy LetterLabel
- Jul 25, 2008 Supplement 6 · Efficacy LabelLetter
- Mar 27, 2007 Supplement 2 · Efficacy LetterLabel
- Feb 23, 2007 Supplement 1 · Efficacy LabelLetter
- Mar 29, 2005 Original approval · Type 3 - New Dosage Form · priority review ReviewLabelLetter
1 products under this application
- BARACLUDE · ENTECAVIR 0.05MG/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Entecavir" as an intervention, any sponsor and status, largest first.
Third Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT05182463 · 5,000 participants (planned) · Start Jan 8, 2022 · Primary completion Dec 13, 2026
Drug: Peginterferon Alfa-2B; Nucleoside Analogs · For: Hepatitis B, Chronic
Sites: Guangzhou, China
- Study on Screening, Verification and Intervention of High-risk Patients With Liver CancerPivotal-lookingStatus unknown
Zhongshan Hospital (Xiamen), Fudan UniversityAcademic, hospital or other
NCT05721300 · 2,215 participants (planned) · Start Feb 10, 2023 · Primary completion Dec 31, 2024
Drug: NAs("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") combined with interferon treatments; NAs ("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") treatments · For: Hepatocellular Carcinoma; Chronic Hepatitis B
Sites: Xiamen, China
Qing XIeAcademic, hospital or other
NCT06323681 · 2,016 participants (planned) · Start Feb 4, 2024 · Primary completion Feb 2027
Drug: Peginterferon α-2b based treatment group; NAs monotherapy group · For: Chronic Hepatitis b
Sites: Shanghai, China
- A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis BStatus unknown
Tongji HospitalAcademic, hospital or other
NCT03357822 · 2,000 participants (planned) · Start Jan 25, 2018 · Primary completion Jan 25, 2022
Drug: Pegylated interferon; Entecavir and 1 more · For: Chronic Hepatitis B
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 12 sites in all
Fang WangAcademic, hospital or other
NCT05792761 · 1,900 participants (planned) · Start May 6, 2021 · Primary completion Dec 31, 2025
Drug: Peginterferon alfa-2b combined and ETV · For: Chronic HBV Infection
Sites: Shenzhen, China
- A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHBPivotal-lookingNot yet recruiting
Shanghai Zhimeng Biopharma, Inc.Industry
NCT07095855 · 1,300 participants (planned) · Start Aug 2025 · Primary completion Jan 2028
Drug: ZM-H1505R 100mg · For: Chronic Hepatitis B
Sites: Changchun, China
- Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B PatientsPivotal-lookingStatus unknown
Zhejiang UniversityAcademic, hospital or other
NCT01148576 · 1,200 participants (planned) · Start Jun 2010 · Primary completion Dec 2011
Drug: entecavir; entecavir and 2 more · For: Chronic Hepatitis B; Hepatic Steatosis
Sites: Hangzhou, China
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01438424 · 1,053 participants · Start Jan 2001 · Primary completion Dec 2009
Drug: Entecavir; Lamivudine · For: Hepatitis B Virus; HBV
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death554
- off label use553
- drug ineffective451
- drug resistance407
- diarrhoea389
- pyrexia372
- fatigue369
- hepatitis b332
- nausea328
- pneumonia309
- platelet count decreased302
- anaemia238
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 15 |
| 2006 | 64 |
| 2007 | 193 |
| 2008 | 160 |
| 2009 | 234 |
| 2010 | 308 |
| 2011 | 317 |
| 2012 | 433 |
| 2013 | 378 |
| 2014 | 654 |
| 2015 | 652 |
| 2016 | 823 |
| 2017 | 761 |
| 2018 | 787 |
| 2019 | 858 |
| 2020 | 740 |
| 2021 | 758 |
| 2022 | 793 |
| 2023 | 783 |
| 2024 | 796 |
| 2025 | 755 |
| 2026 | 537 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Baraclude (Entecavir)
2024 spending
$2.7M
Beneficiaries
268
1,512 claims
Per beneficiary
$9,916
$31.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,773,750 |
| 2021 | $3,454,380 |
| 2022 | $3,079,598 |
| 2023 | $2,808,858 |
| 2024 | $2,657,561 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.
Taplitz RA, Kennedy EB, Bow EJ, et al. · J Clin Oncol 2018 · Practice Guideline, Systematic Review
- Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.
Funk AL, Lu Y, Yoshida K, et al. · Lancet Infect Dis 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis.
Wang N, He S, Zheng Y, et al. · BMC Gastroenterol 2023 · Meta-Analysis, Systematic Review
- Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
Ji D, Chen Y, Bi J, et al. · J Hepatol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Comparison on different traditional Chinese medicine therapies for chronic hepatitis B liver fibrosis.
Dai YK, Fan HN, Hu YH, et al. · Front Pharmacol 2022 · Systematic Review
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.